e-ISSN 2329-0072

Logo

Medical
MSM  BR

AmJCaseRep

Get your full text copy in PDF

The management of Heart Failure – state after publication of European Society of Cardiology Guidelines (2005) and results of CIBIS III Trial

Marcin Barylski, Maciej Banach, Robert Irzmański, Ewa Serwa-Stępień, Jacek Rysz, Piotr Okoński, Jarosław Drożdż

Med Sci Tech 2006; 47(1): RP17-33

ID: 881483


Heart failure is the pathophysiologic state in which the heart, via an abnormality of cardiac function (detectable or not), fails to pump blood at a rate commensurate with the requirements of the metabolizing tissues. Despite recent advances in the management of patients with heart failure, morbidity and mortality rates remain high, with an estimated 5-year mortality rate of 50%. Medical therapy of heart failure focuses on 3 main goals: (1) preload reduction, (2) reduction of systemic vascular resistance (after load reduction), and (3) inhibition of both the RAAS systems and vasoconstrictor neurohumoral factors produced by the sympathetic nervous system in patients with heart failure. In this article, we present the management of chronic heart failure based on European Society of Cardiology Guidelines (2005) and results of CIBIS III Trial. (Clin. Exp. Med. Lett. 2006; 47(1):17-33)

Keywords: therapy, CIBIS III trial, Guidelines

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree